<?xml version="1.0" encoding="UTF-8"?>
<p>Studies [
 <xref rid="B133-pharmaceuticals-13-00313" ref-type="bibr">133</xref>,
 <xref rid="B134-pharmaceuticals-13-00313" ref-type="bibr">134</xref>] have shown that echinacea can reduce the severity and/or duration of acute respiratory infections when taken at the beginning of the disease when the first symptoms appear. 
 <italic>Echinacea purpurea</italic> reduces the risk of recurrent respiratory infections and the incidence of complications. The high content of essential oils, antioxidants, organic acids, vitamins of groups A, B and E. Echinacea-based preparations boosts the immune system and helps the body to fight flu viruses, herpes and SARS. The immunomodulatory, antiviral and anti-inflammatory effects of this plant can serve as a basis for research on its activities in relation to COVID-19.
</p>
